Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.
about
Energy disruptors: rising stars in anticancer therapy?Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based SelectionChemical metabolic inhibitors for the treatment of blood-borne cancersBcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activationAutophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targetingRegulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cellsPathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells.Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responsesTargeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy.Metformin targets multiple signaling pathways in cancer.Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors.Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphomaAMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies.New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells.Targeting PI3K/AKT/mTOR network for treatment of leukemia.Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?5-Aminoimidazole-4-carboxamide ribonucleoside induces differentiation of acute myeloid leukemia cells.Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.Adenine causes cell cycle arrest and autophagy of chronic myelogenous leukemia K562 cells via AMP-activated protein kinase signaling.Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells.Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms.Metformin, an Anti-diabetic Drug to Target Leukemia
P2860
Q26771300-B24AE96F-0501-4566-B45F-812D0D95794AQ28552598-8F9E3EB4-AB68-4A6E-B5BE-D5C6C512E486Q28822335-60E777C9-E448-4C14-AB1A-18D43F36385CQ30395557-2D7A3FB4-9305-4F5A-9FAD-006BED77DF8AQ33645356-08CEEEA9-86A9-4046-AE00-07BE533957E5Q33752594-14C1AD2F-2F5F-43D7-B766-464DC0D8B014Q35048118-EE5DD886-1FCD-48ED-A7A7-64FA836D10A2Q35836470-949049B2-BDCB-486C-8045-884C0AF4D31DQ35931271-98A173F8-A192-4C6A-8F86-699B7A65CD5CQ36901497-FF51E75A-CF1F-4AE1-BB51-6B2D4C1641DBQ37011502-9CDC35E8-8342-4FF6-A0DC-949257AC5205Q37609790-84C4A3FB-282E-4738-8876-D332330AC281Q37692470-8755E802-BA67-4DE9-AD13-CA7F672454D8Q37718466-C41514D6-B423-4CB2-8084-DC523A0192DDQ37976243-F89EF212-1B29-4260-933A-99A32591262FQ38017727-B46C17AE-ED92-4704-A0EB-1B4B524A5D05Q38187997-317292EE-7D9D-4CA4-B5ED-A5B9AA740A44Q38364871-19105690-CBFC-4070-B755-AD374AE81693Q38401664-8FBD9ADF-B49A-492D-A2BE-4A451FA817FBQ38606849-5443F3D3-9E77-4C4D-B264-2553B1A9980AQ39041458-89D05D44-662D-4A8C-8455-99183F96EB99Q39326047-23669E24-7893-4DA7-8A87-17361D0902B8Q44147547-B555011A-2EA5-469E-AB60-48EEF9B13DE4Q47420917-404B1BEB-5C9A-4D1D-87EC-B69003A5746BQ51748677-BD19DEB8-3DB7-43F7-8419-04E0731C8C96Q58790135-0DF089D2-717C-4C3E-850C-00D68B4B498F
P2860
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.
@ast
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.
@en
type
label
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.
@ast
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.
@en
prefLabel
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.
@ast
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.
@en
P2093
P2860
P1433
P1476
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.
@en
P2093
Eliza Vakana
Heather Glaser
Jessica K Altman
Leonidas C Platanias
Nicholas J Donato
P2860
P304
P356
10.1182/BLOOD-2011-01-332783
P407
P577
2011-10-21T00:00:00Z